Holen Sie sich die Stockscreener-App
1.05
3.67%
-0.04
Handel nachbörslich:
1.06
0.01
+0.95%
Schlusskurs vom Vortag:
$1.09
Offen:
$1.06
24-Stunden-Volumen:
26,057
Relative Volume:
0.11
Marktkapitalisierung:
$4.31M
Einnahmen:
$79,300
Nettoeinkommen (Verlust:
$-6.92M
KGV:
-0.0553
EPS:
-18.9818
Netto-Cashflow:
$-5.34M
1W Leistung:
+5.69%
1M Leistung:
-18.60%
6M Leistung:
-53.95%
1J Leistung:
+50.00%
1-Tages-Spanne:
$1.04
$1.0698
1-Wochen-Bereich:
$0.91
$1.09
52-Wochen-Spanne:
$0.60
$8.9999
Virax Biolabs Group Ltd Stock (VRAX) Company Profile
Firmenname
Virax Biolabs Group Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie VRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRAX
Virax Biolabs Group Ltd
|
1.05 | 4.31M | 79,300 | -6.92M | -5.34M | -18.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 125.74B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.57B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.40B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.36B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Virax Biolabs Group Ltd Stock (VRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-31 | Eingeleitet | H.C. Wainwright | Buy |
Virax Biolabs Group Ltd Aktie (VRAX) Neueste Nachrichten
Virax Biolabs Group (NASDAQ:VRAX) Trading Up 6.9% – Here’s What Happened - Defense World
FY2025 Earnings Estimate for VRAX Issued By HC Wainwright - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Coverage Initiated by Analysts at HC Wainwright - Defense World
Virax Biolabs' Investigational Diagnostic Tests Has An Attractive Market Opportunity', Analyst Initiates With Buy Rating - Yahoo Finance
Virax Biolabs Group Ltd.’s Innovative Diagnostics and Strategic Collaborations Justify Buy Rating - TipRanks
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Update - Defense World
Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next? - Defense World
Virax Biolabs Launches Clinical Study on T Cell Dysfunction - TipRanks
Virax Biolabs begins UK clinical study on T cell dysfunction - Investing.com India
Breakthrough T Cell Study: Virax Targets Long COVID and Chronic Fatigue Diagnosis Revolution - StockTitan
Virax Biolabs Highlights T-Cell Dysfunction in Post-Infection Syndromes - TipRanks
Virax Biolabs shares T-Cell dysfunction findings - Investing.com India
Virax Biolabs shares T-Cell dysfunction findings By Investing.com - Investing.com South Africa
Game-Changing Long COVID Diagnostic: Virax's New T-Cell Test Shows Promising Results - StockTitan
Virax Biolabs to Present at World Immune Regulation Meeting - TipRanks
Can Virax's T-Cell Research at WIRM 2025 Advance Post-Infection Syndrome Treatment? - StockTitan
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Up 205.8% in February - The AM Reporter
Cosmos Health expands distribution of Avian Influenza kits - MSN
Short Interest in Virax Biolabs Group Limited (NASDAQ:VRAX) Expands By 205.8% - Defense World
Virax Biolabs aligns with US vaccine transparency efforts By Investing.com - Investing.com South Africa
Virax Biolabs Aligns with US Health Department on Vaccine Transparency - TipRanks
How Virax's Vaccine Testing Tech Could Capitalize on New Government Transparency Push - StockTitan
EXCLUSIVE: Virax Biolabs Says Its Tech Fits RFK Jr.'s HHS Goals On Vaccine Transparency - Benzinga
Contrasting Virax Biolabs Group (NASDAQ:VRAX) & Oruka Therapeutics (NASDAQ:ORKA) - Defense World
Market Watch: Virax Biolabs Group Ltd (VRAX)’s Noteworthy Drop, Closing at 1.71 - The Dwinnex
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 33.9% in January - Armenian Reporter
Cosmos Health Signs Expanded Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Saudi Arabia, the UAE, Qatar, and Kuwait - Yahoo Finance
Cosmos Health secures exclusive distribution agreement with Virax Biolabs - Yahoo Finance
Cosmos Health Secures Exclusive Distribution Agreement with Virax Biolabs for Avian Influenza Virus PCR Kits in Greece and Cyprus, with Additional Rights in Select European and GCC Countries - Lelezard
Virax Biolabs Group Ltd (VRAX) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Virax Biolabs stock soars 45% on Mpox detection kit deal: What you need to know - MSN
Virax Biolabs Group Limited (NASDAQ:VRAX) Short Interest Down 38.5% in December - Defense World
Virax Biolabs Achieves Shareholder Approvals at Adjourned Annual Meeting - TipRanks
Stock Region Signal Report - substack.com
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Virax Biolabs Announces Strategic Goals and Developments for 2025 - TipRanks
Virax Biolabs Advances T-Cell Platform with $7.3M War Chest, Expands European Distribution Network - StockTitan
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect across the European Union, Norway, and Switzerland - Marketscreener.com
Virax Biolabs Expands ImmuneSelect Reach in Europe - TipRanks
Virax Biolabs Announces Agreement with Tebubio to Expand Distribution of ImmuneSelect Across the European Union, Norway, and Switzerland - Yahoo Finance
Virax Biolabs Group First Half 2025 Earnings: US$0.89 loss per share (vs US$1.64 loss in 1H 2024) - Simply Wall St
Virax Biolabs Sees Asset Growth Amid Financial Loss - TipRanks
ARMISTICE CAPITAL, LLC Acquires New Stake in Virax Biolabs Group Ltd - GuruFocus.com
Virax Biolabs announces 2024 annual meeting - Investing.com India
Finanzdaten der Virax Biolabs Group Ltd-Aktie (VRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
36.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):